RXI PHARMACEUTICALS CORPORATION (RXII:NASDAQ)
RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of human diseases.
RXi was founded by world-leading researchers in the field of RNAi, began operations in January of 2007 and started trading on the Nasdaq in March of 2008
Yearly Figures
| (in thousands, except per share amounts) |
| FYE: 12/31 |
2009 |
2008 |
2007 |
2006 |
| Net Income |
(18,387) |
(14,373) |
|
|
| Earnings Per Share |
(1.24) |
(1.09) |
|
|
Quarterly Figures
| (in thousands, except per share amounts) |
| | Second Quarter |
| FYE: 12/31 |
6/30/10 |
6/30/09 |
| Net Revenues |
$ |
$ |
| Net Income |
(2,141) |
(5,081) |
| Earnings Per Share |
(0.12) |
(0.37) |
|
